Recent studies suggest that OPG may be a new therapeutic agent for bone loss associated with metabolic diseases such as osteoporosis and rheumatoid arthritis (Bucay et al, 1998; Kong et al, 1999; Kostenuik et al, 2001; Redlich et al, 2002). The gene discussed is TNFRSF11B; the disease is osteoporosis.